XELPROS Drug Patent Profile

Which patents cover Xelpros, and when can generic versions of Xelpros launch?

Xelpros is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has nineteen patent family members in seventeen countries.

The generic ingredient in XELPROS is latanoprost. There are twenty drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xelpros

A generic version of XELPROS was approved as latanoprost by AMRING PHARMS on March 22^nd, 2011.

Summary for XELPROS

International Patents:	19
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	79
Patent Applications:	6,239
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for XELPROS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XELPROS
What excipients (inactive ingredients) are in XELPROS?	XELPROS excipients list
DailyMed Link:	XELPROS at DailyMed

See drug prices for XELPROS

Pharmacology for XELPROS

Drug Class

Prostaglandin Analog

Anatomical Therapeutic Chemical (ATC) Classes for XELPROS

S01EE	Prostaglandin analogues
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for XELPROS

XELPROS is protected by two US patents.

Patents protecting XELPROS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	XELPROS	latanoprost	EMULSION;OPHTHALMIC	206185-001	Sep 12, 2018		RX	Yes	Yes
Sun Pharm	XELPROS	latanoprost	EMULSION;OPHTHALMIC	206185-001	Sep 12, 2018		RX	Yes	Yes			Y

International Patents for XELPROS

See the table below for patents covering XELPROS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2008344909
Singapore	185273	OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN
Japan	2011508724
Japan	5646331
Mexico	2010004211	COMPOSICION OFTALMICA QUE COMPRENDE UNA PROSTAGLANDINA. (OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN.)
China	101835473
South Korea	101510185

Supplementary Protection Certificates for XELPROS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0364417	SPC/GB97/014	United Kingdom		PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
3461484	21C1024	France		PRODUCT NAME: ASSOCIATION DE NETARSUDIL OU L'UN DE SES SELS ET DE LATANOPROST; REGISTRATION NO/DATE: EU/1/20/1502 20210108
0364417	61/1997	Austria		PRODUCT NAME: LATANOPROST UND SEINE THERAPEUTISCH AKTIVEN UND PHYSIOLOGISCH ANNEHMBAREN DERIVATE; NAT. REGISTRATION NO/DATE: 1-22019 19970627; FIRST REGISTRATION: SE 12716 19960718
0364417	C970039	Netherlands		PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718
3461484	C202130024	Spain		PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107
3461484	2021C/515	Belgium		PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
3461484	122021000036	Germany		PRODUCT NAME: LATANOPROST, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND NETARSUDIL MESYLAT; REGISTRATION NO/DATE: EU/1/20/1502 20210107